Entering text into the input field will update the search result below

Biogen biosimilar to Roche’s arthritis therapy goes under EU review

Sep. 30, 2022 7:59 AM ETBiogen Inc. (BIIB) StockRHHBY, RHHBFBy: Dulan Lokuwithana, SA News Editor

Actemra

Sohel_Parvez_Haque/iStock via Getty Images

  • Biogen (NASDAQ:BIIB) announced Friday that the European Medicines Agency (EMA) accepted its marketing application for BIIB800, a biosimilar to Roche’s (OTCQX:RHHBY) (OTCQX:RHHBF) arthritis therapy RoACTEMRA.
  • Also known as Actemra or tocilizumab, RoACTEMRA is indicated in Europe

Recommended For You

More Trending News

About BIIB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BIIB--
Biogen Inc.